Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern www.swissmedic.ch Workshop 2 - Paragraph 13 TPA 2nd Follow-up Information.

Slides:



Advertisements
Similar presentations
© 2011 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International.
Advertisements

Czech approach to Regulatory Impact Assessment Prof. Michal Mejstřík Chairman of Regulatory Impact Assessment Board (RIAB) of the Czech Government Legislative.
1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
BASELINE STANDARD UNFCCC secretariat workshop
Overview of Transition to Single Streams of Funding REGIONAL GLOBAL FUND GRANT CONSOLIDATION WORKSHOP DATE MODULE 2 1.
PCMH Supplemental Grant Interim Reports Technical Assistance Call March 28, 2012 Nina Brown, MPH, CHES, Public Health Analyst, OQD Michelle Bright, Public.
GMP Document and Record Retention
The Gateway What is the Gateway? Gateway Options
DoD Information Technology Security Certification and Accreditation Process (DITSCAP) Phase III – Validation Thomas Howard Chris Pierce.
30. Conference of Directors of EU Paying Agencies Workshop1: The possibilities for optimizing the processes of implementation of direct payments Agency.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 QIS/QOS: The new PQP quality templates.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Navigating and Preparing a HRSA Application Responding to a Funding Opportunity Announcement Sarah Hammond, Grants Policy Analyst HRSA’s Office of Federal.
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
IMPLEMENTATION ISSUES
EU-TURKEY CHAMBER FORUM PROJECT (ETCF) ETCF is funded by the European Union. 1 EU-TURKEY CHAMBER FORUM EU TURKEY CHAMBERS PARTNERSHİP GRANT SCHEME PROCUREMENT.
Advisory group on fruit and vegetables 7 March 2008
J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Electronic Submissions – eCTD Advantages Dr Milind Joshi.
Best Archival Practice in the Regulation of Medicines: Work on the Guidelines for Agencies for Medicinal Products Ph.D. Arian Rajh Agency for Medicinal.
TEMPUS INFORMATION DAYS Tajikistan, 18 November 2011 Alba-Chiara Tiberi, Project Officer EACEA TEMPUS IV- FIFTH CALL FOR.
1 The Washington State Board of Education Applying to Authorize: Authorizer Application and Evaluation Jack Archer, Senior Policy Analyst State Board of.
Overview of FDA's Regulatory Framework for PET Drugs
Main Requirements on Different Stages of the Licensing Process for New Nuclear Facilities Module 4.10 Documents to be Submitted to the Regulatory Body.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
ECENA Workshop on Benchmarking and Progress Monitoring in Environmental Enforcement and Compliance Szentendre, March 29-30, 2007 Assessment Tools and Methods.
M ODULE 6 PART 1: Planning and Stakeholder Management GLOBAL FUND GRANT CONSOLIDATION WORKSHOP DATE.
Health and Consumers Health and Consumers Commission view on the implementation of Regulation (EC) No 1107/2009 ECPA/ECCA Brussels Regulatory Conference.
CTD Dossier Preparation K. Srikantha Reddy Sr
DESCRIPTION OF THE MONITORING AND EVALUATION SYSTEM IN POLAND Action Plan and the Two-year NRN Operational Plans.
Approximation of legislation to the internal market acquis An EU funded project managed by European Agency for Reconstruction Directive 89/106/EEC on Construction.
SAPRAA 5 Sept 2008 eCTD An overview of the full day presentation by Dr Olaf Schoepke at the SAAPI conference in July 2008.
The assessment process in “stringent” authorities Regine Lehnert Training workshop: Regulatory requirements for registration of Artemisinin based combined.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)
Agreement concerning the adoption of uniform conditions for periodical technical inspections of wheeled vehicles and the reciprocal recognition of such.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 1 – Case Study 2nd Follow-up Information Meeting.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern From Step 2 to Step 3 of the eCTD Introduction 2nd Follow-up.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Swissmedic’s future steps 2nd Follow-up Information Meeting.
Consumers, Health, Agriculture and Food Executive Agency 3rd Health Programme The Electronic Submission System (JA 2015) Georgios MARGETIDIS.
INTERREG III B CADSES Neighbourhood Programme Administrative and Financial Aspects of Hydrocare Project Dr. Janka Strakova Project contact.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 3 – Life Cycle Management 2nd Follow-up Information.
Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern PSUR und E2E/RMP-Updates 2nd Follow-up Information Meeting.
An Overview of eCTD for CMC Specialists Dr Martin Moxham June 2010 iRegulatory Ltd, 1 Viewpoint Office Village, Babbage Road, Stevenage, SG1 2EQ, United.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
FUSE TEMPUS Project Coordination Meeting Belgrade University, 27 and 28 November, 2014 INTERMEDIATE REPORT (IR) PREPARATION (+ Statement of the Costs Incurred.
Use and Conduct of Safety Analysis IAEA Training Course on Safety Assessment of NPPs to Assist Decission Making Workshop Information IAEA Workshop Lecturer.
Experience from a Generic Dossier Dr. Roger Bolten, 16 th March 2011.
Validation Gary Gensinger Deputy Director Office of Business Process Support Center for Drug Evaluation and Research.
An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry.
An agency of the European Union EU ISO IDMP Roadmap to enable eprescription cross-borders Towards a trans-atlantic solution to univocally identify medicinal.
mSCOA COMPLIANCE – ARE YOU READY?
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Periodic Safety Update Reports (PSUR)
Chisinau, Republic of Moldova 2017
CTD Content Management
PROJECT MANUAL Galina Georgieva Project Officer
Handling ongoing variations concerning same document
Median 25th and 75th percentile
UA – Same biocidal product SPC translation review
Gibraltar Financial Services Commission
EU SUBMISSION BY Haripriya & Revathy.
EMA: The European Medicines Agency
THE OECD WORK SHARING WORK PROGRAMME FOR BIOCIDES
FY19 Federal Grant Monitoring: Titles I, II, IV
Changing the Reference Member State (RMS)
Recommendations to facilitate assessment of new application procedures
WG E on Priority Substances
EU Food Safety Requirements: - Hygiene of Foodstuffs -
Presentation transcript:

Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 2 - Paragraph 13 TPA 2nd Follow-up Information Meeting with Workshops – Step 3 Dr. Cornelia Bigler, Swissmedic Jörg Schnitzler, Astellas 16th March 2011

2 Overview 1.Formal Preparation of the Submission 2.Technical Preparation 3.Pro‘s and Con‘s of Submissions according to Paragraph 13 4.Tips and Tricks, Questions

3 Formal Preparation of the Submission (I) Example-Pill  Application type: na-ngf  Galenic Form: Tablets  Paragraph 13: yes  Central European Authorisation

4 Formal Preparation of the Submission (II) Questions  What documents do I have to consider?  Put the milestones in the right order

5 Formal Preparation of the Submission (III) Questions  Which application types can be submitted according to paragraph 13 TPA in eCTD Format?  Which applications can lead to a faster approval?

6 Formal Preparation of the Submission (IV) Question  What forms do I have to submit?  /00067/00331/00631/in dex.html?lang=en

7 Formal Preparation of the Submission (V) Questions  What documents regarding correspondance do I have to submit if the application is based on an EU-CP?  Where do I put FDA Assessment Reports?

8 Formal Preparation of the Submission (VI) Questions  Where do I find the requirements for Module 1?  Where do I find an example of a tracking table?

9 Formal Preparation of the Submission (VII) Questions  Can primary and secondary packaging of the product in Switzerland differ from the one authorised in the EU?  What other differences between the authorisation in a foreign country and the application submitted to Swissmedic are allowed?

10 Formal Preparation of the Submission (VIII) Questions  How do I maintain the lifecycle after approval? Variation of product information

11 Overview 1.Formal Preparation of the Submission 2.Technical Preparation 3.Pro‘s and Con‘s of Submissions according to Paragraph 13 4.Tips and Tricks, Questions

12 Technical Preparation – Initial Application Questions Example: an existing EU dossier approved in 2007  How to prepare the inital application?  Which documents are required beside the reference dossier?

Paragraph 13 – Initial Submission of Reference Dossier and Swiss M1 Reference Dossier (e.g. EU) Swiss Dossier Exact copy of all approved sequences (reference dossier will not undergo technical validation) At the time of the initial paragraph 13 application Swiss eCTD consists only of the Swiss Module 1 13

14 Technical Preparation - Consolidation Questions Paragraph 13 granted for dossier – next step:  How to combine Swiss eCTD and reference dossier for future lifecycle?

Paragraph 13 – Incorporating Reference M2-5 Life Cycle into Swiss eCTD Reference Dossier (e.g. EU) Swiss Dossier CH M1 Current approved status Future life cycle just in Swiss eCTD 15

16 Technical Preparation - Correspondence Questions  How to include Module 1 documents from the reference dossier into the Swiss eCTD in M1?  How to include correspondence between applicant and reference country?  What should be hyperlinked?

Paragraph 13 eSubmission – merge dossiers Copy as new document Delete EU M1 Include 1.7 Merge reduced EU with §13 CH M1 Reference Dossier (e.g. EU) 17

18 Overview 1.Formal Preparation of the Submission 2.Technical Preparation 3.Pro‘s and Con‘s of Submissions according to Paragraph 13 4.Tips and Tricks, Questions

Pro’s of Submissions according to Paragraph 13 (I)  Quick preparation of initial dossier possible as just Swiss Module 1 and an exact copy of reference dossier required.  Reference dossier can be used for initial application without any changes or rework (content validation, no technical validation).  Merging of reference dossier and Swiss eCTD while process ongoing (i.e. without clock-stop). 19

Pro’s of Submissions according to Paragraph 13 (II)  Free-of-charge validation tools allow to check upfront for technical compliance of submission.  Even submissions in NeeS or paper can be submitted according to Paragraph 13, but require more rework in order to merge life cycles.  Parallel submission in Switzerland and reference country and later switch to Art 13 after successful approval in reference country possible. 20

Con’s of Submissions according to Paragraph 13 (I)  Limitation to dossiers approved within the last 5 years.  Technical rework might be required to ensure compliance with latest validation criteria for older dossiers (up to 5 years) when merging M2-5 of the reference dossier into the Swiss eCTD. 21

Con’s of Submissions according to Paragraph 13 (II)  Correspondence between applicant and reference country and specific Module 1 documents e.g. Response to Questions need to be provided as part of the Swiss eCTD.  In case of contradictory assessments in the reference countries (e.g. different assessment in US vs. EU) Swissmedic carries out its own evaluation. 22

23 Overview 1.Formal Preparation of the Submission 2.Technical Preparation 3.Pro‘s and Con‘s of Submissions according to Paragraph 13 4.Tips and Tricks, Questions

24 Swissmedic’s Review Tool

Technical Hurdles Rework of reference dossier required?  Up to 5 years old  Valid according to older validation criteria?  Valid according to latest validation criteria?  PDF v1.4  Hyperlinks QCed after merging into CH eCTD?  ‘Incorrect’ filenames  Node-extensions  Differences in validation reports 25

26 Tips and Tricks  Hyperlinking of product information is not required  Module 1.7.1: EU Responses to LoQ, not only for EMA, but also for DCP (no Hyperlinking required)  Evaluation report(s), other assessments and the related correspondence that led to the decisions of the reference authority have to be submitted in full (VAM Art 5a, section 1)  Read the guidance and supporting documents

27 Thank you for your attention! Any Questions?